ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GSK Gsk Plc

1,733.50
5.00 (0.29%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  5.00 0.29% 1,733.50 1,732.50 1,733.00 1,739.50 1,724.50 1,733.00 4,237,056 16:35:18
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.48 71.35B

GlaxoSmithKline Raises Outlook as 3Q Revenue, Profit Grow

30/10/2019 12:52pm

Dow Jones News


Gsk (LSE:GSK)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Gsk Charts.

By Carlo Martuscelli

 

GlaxoSmithKline PLC (GSK.LN) upgraded its guidance on Wednesday after it posted growing profit in the third quarter on revenue that beat market expectations.

The British pharmaceutical company made a pretax profit of 1.95 billion pounds ($2.51 billion) in the third quarter, compared with GBP1.71 billion the year earlier. Turnover increased 16% to GBP9.39 billion, beating analyst forecasts of GBP9.04 billion.

Meanwhile adjusted earnings per share--a metric closely watched by analysts--rose to 38.6 pence from 35.5 pence in the third quarter of 2019.

Glaxo said that it is now sees full-year adjusted EPS flat when accounting for currency effects. Previously, the company guided for a decrease of between 3% to 5%.

It confirmed that it was on track to file a new drug application for its cancer drug Zejula by the end of the year having reported positive data from a clinical trial in September that looked at the medicine as a treatment for ovarian cancer.

The company declared a quarterly dividend of 19 pence a share and confirmed its 80 pence total target for the full-year.

 

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com; @carlomartu

 

(END) Dow Jones Newswires

October 30, 2019 08:37 ET (12:37 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

1 Year Gsk Chart

1 Year Gsk Chart

1 Month Gsk Chart

1 Month Gsk Chart

Your Recent History

Delayed Upgrade Clock